In brief: A new trial in the UK asks whether or not the NeuRX DPS improves the quality of life and extends survival of people with ALS.
The NeuRX Diaphragm Pacing System. Image: Synapse Biomedical.
Researchers in the UK will soon be putting the NeuRX diaphragm pacing system (DPS) to the test to determine whether the device in combination with non-invasive ventilation (NIV) improves the quality of life and extends survival of people with ALS experiencing respiratory weakness. The clinical trial, known as Diaphragm Pacing In Motor Neuron Disease (DiPALS), will be conducted at up to 10 National Health Service (NHS) hospitals in the UK. Trial participants will receive either NIV or NIV and be implanted with the NeuRX DPS. 108 people with ALS are expected to enroll. The trial is expected to be completed in 2014.
To read more about the NeuRx diaphragm pacer and how the device might benefit people with ALS, read our recent feature DPS Sleep.
Scherer, K. and Bedlack, R.S (2012) Diaphragm pacing in amyotrophic lateral sclerosis: a literature review. Muscle and Nerve 46(1), 1-8. Abstract | Full Text (Subscription Required)
Marion, D.W. (2011) Diaphragm Pacing. UpToDate. Excerpt | Full Text (Subscription Required)
Diaphragm Pacing in Motor Neuron Disease (DiPALS) Study Contact | ALS TDI | Website
Update 1/25/13: The trial is now ongoing. At least 7 sites in the UK are recruiting people with ALS MND including the Royal Free Hospital in London and the John Radcliffe Hospital in Oxford.